N4P

N4 Pharma to host webinar on collaboration agreement with SRI International

Join N4 Pharma Plc for a pre-recorded webinar on their recent Collaboration Agreement with SRI International Inc. Available on 7 May 2024 at 10:00 BST...

N4 Pharma collaborates with SRI International to combine Nuvec and FOX Three MGS technology

N4 Pharma Plc partners with SRI International to combine Nuvec® with FOX Three MGS, aiming to enhance nucleotide therapies for cancer and vaccines...

N4 Pharma achieves material advancements in the capabilities of Nuvec®

N4 Pharma Plc (LON:N4P) unveils its audited results for 2023, showcasing advancements in its innovative Nuvec® delivery system for cancer treatments and vaccines...

N4 Pharma provides Positive Update on Nuvec® oral delivery research

N4 Pharma Plc (LON:N4P) updates on successful oral delivery research for Nuvec® system, showing potential for cancer treatment and vaccines. CEO Nigel Theobald shares insights...

N4 Pharma provides encouraging update on its ongoing in vitro siRNA research work

N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec® delivery system for cancer treatments...

N4 Pharma’s Nuvec® granted patent in India

N4 Pharma Plc announces the granting of a patent for its Nuvec® delivery system in India, adding to its global portfolio of granted patents...

N4 Pharma’s Nanogenics signs contract for pre-clinical study of ECP105 for Glaucoma treatment

N4 Pharma's subsidiary, Nanogenics, has signed a contract to prepare its ECP105 product for pre-clinical studies in Glaucoma treatment...
Search

Funds

N4P

N4 Pharma to host webinar on collaboration agreement with SRI International

Join N4 Pharma Plc for a pre-recorded webinar on their recent Collaboration Agreement with SRI International Inc. Available on 7 May 2024 at 10:00 BST...

N4 Pharma collaborates with SRI International to combine Nuvec and FOX Three MGS technology

N4 Pharma Plc partners with SRI International to combine Nuvec® with FOX Three MGS, aiming to enhance nucleotide therapies for cancer and vaccines...

N4 Pharma achieves material advancements in the capabilities of Nuvec®

N4 Pharma Plc (LON:N4P) unveils its audited results for 2023, showcasing advancements in its innovative Nuvec® delivery system for cancer treatments and vaccines...

N4 Pharma provides Positive Update on Nuvec® oral delivery research

N4 Pharma Plc (LON:N4P) updates on successful oral delivery research for Nuvec® system, showing potential for cancer treatment and vaccines. CEO Nigel Theobald shares insights...

N4 Pharma provides encouraging update on its ongoing in vitro siRNA research work

N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec® delivery system for cancer treatments...

N4 Pharma’s Nuvec® granted patent in India

N4 Pharma Plc announces the granting of a patent for its Nuvec® delivery system in India, adding to its global portfolio of granted patents...

N4 Pharma’s Nanogenics signs contract for pre-clinical study of ECP105 for Glaucoma treatment

N4 Pharma's subsidiary, Nanogenics, has signed a contract to prepare its ECP105 product for pre-clinical studies in Glaucoma treatment...
Search

Funds

N4P

FTSE 100

Funds